184 related articles for article (PubMed ID: 25035653)
1. Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.
Li X; Yan Z; Kong D; Zou W; Wang J; Sun D; Jiang Y; Zheng C
Chin J Cancer Res; 2014 Jun; 26(3):268-76. PubMed ID: 25035653
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials.
Gergal Gopalkrishna Rao SR; Bugazia S; Dhandapani TPM; Tara A; Garg I; Patel JN; Yeon J; Memon MS; Muralidharan A; Khan S
Cureus; 2021 Sep; 13(9):e17835. PubMed ID: 34527499
[TBL] [Abstract][Full Text] [Related]
3. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data.
Bohlius J; Tonia T; Nüesch E; Jüni P; Fey MF; Egger M; Bernhard J
Br J Cancer; 2014 Jul; 111(1):33-45. PubMed ID: 24743705
[TBL] [Abstract][Full Text] [Related]
4. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.
Zhan P; Wang Q; Qian Q; Yu LK
Chin Clin Oncol; 2012 Dec; 1(2):19. PubMed ID: 25841397
[TBL] [Abstract][Full Text] [Related]
5. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
[TBL] [Abstract][Full Text] [Related]
6. Erythropoiesis-stimulating agents as replacement therapy for blood transfusions in critically ill patients with anaemia: A systematic review with meta-analysis.
Wijnberge M; Rellum SR; de Bruin S; Cecconi M; Oczkowski S; Vlaar AP
Transfus Med; 2020 Dec; 30(6):433-441. PubMed ID: 32935404
[TBL] [Abstract][Full Text] [Related]
7. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.
Kang J; Park J; Lee JM; Park JJ; Choi DJ
Int J Cardiol; 2016 Sep; 218():12-22. PubMed ID: 27209352
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin or darbepoetin for patients with cancer.
Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis.
Kei T; Mistry N; Curley G; Pavenski K; Shehata N; Tanzini RM; Gauthier MF; Thorpe K; Schweizer TA; Ward S; Mazer CD; Hare GMT
Can J Anaesth; 2019 Jun; 66(6):716-731. PubMed ID: 30924000
[TBL] [Abstract][Full Text] [Related]
11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of chemotherapy-induced anemia].
Kadokura G; Katsumata N
Gan To Kagaku Ryoho; 2014 Apr; 41(4):416-20. PubMed ID: 24743356
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.
Gao S; Ma JJ; Lu C
Tumour Biol; 2014 Jan; 35(1):603-13. PubMed ID: 23959477
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.
Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593
[TBL] [Abstract][Full Text] [Related]
16. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
[TBL] [Abstract][Full Text] [Related]
17. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
18. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A
J Clin Oncol; 2019 May; 37(15):1336-1351. PubMed ID: 30969847
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M
JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
